Methylphenidate
- Generic Name
- Methylphenidate
- Brand Names
- Adhansia, Aptensio, Biphentin, Concerta, Cotempla, Daytrana, Foquest, Jornay, Metadate, Methylin, Quillichew, Quillivant, Relexxii, Ritalin
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19NO2
- CAS Number
- 113-45-1
- Unique Ingredient Identifier
- 207ZZ9QZ49
- Background
Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve ...
- Indication
Methylphenidate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older and for the treatment of narcolepsy.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Narcolepsy
- Associated Therapies
- -
OT and Social Cognition in Children With ADHD: Impact of MPH
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2018-12-28
- Lead Sponsor
- Shalvata Mental Health Center
- Target Recruit Count
- 90
- Registration Number
- NCT03788902
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
- Conditions
- Interventions
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 500
- Registration Number
- NCT03781752
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
- Conditions
- Interventions
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 44
- Registration Number
- NCT03781765
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients with Prostate Cancer
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT03772834
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Brain Connectivity in Attention Deficit Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- King's College London
- Target Recruit Count
- 60
- Registration Number
- NCT03709940
- Locations
- 🇬🇧
King's College London, London, United Kingdom
Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)
- Conditions
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Craig Rush
- Target Recruit Count
- 19
- Registration Number
- NCT03575403
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Methylphenidate and Physical Activity to Reduce Cancer Related Fatigue Due to Anti PD1 Immunotherapy
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 212
- Registration Number
- NCT03525873
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Behavioral Effects of Drugs: Inpatient (35)
- Conditions
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Craig Rush
- Target Recruit Count
- 9
- Registration Number
- NCT03519022
- Locations
- 🇺🇸
University of Kentucky Medical Center, Lexington, Kentucky, United States
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Conditions
- Interventions
- Drug: Tranexamic acid (TXA)Drug: HydrocodoneDrug: labetalolDrug: metforminDrug: nifedipineDrug: oxycodoneDrug: clindamycinDrug: azithromycinDrug: escitalopramDrug: sertralineDrug: CiprofloxacinDrug: ondansetronDrug: DoxycyclineDrug: LevofloxacinDrug: MethylphenidateDrug: CitalopramDrug: SumatriptanDrug: CyclobenzaprineDrug: FurosemideDrug: RosuvastatinDrug: GabapentinDrug: HydrochlorothiazideDrug: HydroxyureaDrug: TrazodoneDrug: TopiramateDrug: ValganciclovirDrug: RemdesivirDrug: VenlafaxineDrug: VerapamilDrug: FluvoxamineDrug: AnakinraDrug: TocilizumabDrug: AmoxicillinDrug: BupropionDrug: BuprenorphineDrug: LevetiracetamDrug: ParoxetineDrug: Duloxetine
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1600
- Registration Number
- NCT03511118
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Loma Linda University Health, Loma Linda, California, United States
Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity
- Conditions
- Interventions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 3
- Registration Number
- NCT03481959
- Locations
- 🇫🇷
Peyret, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.